Vivos Inc. Expands IsoPet® Therapy with New Clinic Partnership
Vivos Inc. (OTCQB: RDGL) has recently taken a significant step in enhancing its offerings for animal cancer treatment by certifying a new clinic dedicated to IsoPet® Precision Radionuclide Therapy™. The announcement signals Vivos Inc.'s commitment to expanding the accessibility and effectiveness of this innovative cancer treatment for small animals.
Introducing NorthStar Vets to IsoPet Therapy
The newly certified clinic, NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, now provides comprehensive emergency and trauma care, along with specific specialty services geared towards small animals. Their recent approval to administer IsoPet therapy marks a crucial addition to their existing range of treatments.
Commitment to Expanding Access
Dr. Michael K. Korenko emphasized the importance of expanding the number of clinics certified for IsoPet therapy. He noted that certification not only offers a lower-cost alternative compared to other treatments requiring hefty capital investments but also fosters a collaborative environment among veterinarians and oncologists committed to its success. Vivos provides the necessary training and support as clinics navigate the complexities of obtaining or updating their radioactive material licenses.
Understanding the IsoPet Therapy Process
IsoPet therapy utilizes advanced Yttrium-90 based technology to deliver precise and targeted treatment for tumors. This innovative technique administers radiation directly to the tumor site, minimizing side effects typically associated with traditional external radiation therapies. By embedding a radioactive isotope within the tumor area, IsoPet can provide a higher dose of treatment without impacting surrounding healthy tissues.
Benefits of RadioGel® in Cancer Treatment
The RadioGel® product, utilized alongside IsoPet®, is designed to retain its therapeutic properties at room temperature and gel upon injection into the tumor. This method helps secure the radioactive particles in place, ensuring that the radiation remains localized, maximizing its efficacy while protecting adjacent organs from exposure.
Evidencing Effectiveness through Research
Research conducted at prestigious veterinary institutions has demonstrated the safety and effectiveness of IsoPet therapy. Studies examining the treatment of feline sarcoma and canine soft tissue sarcomas have confirmed its therapeutic benefits. Notably, the FDA recognized IsoPet as a medical device, facilitating its integration into veterinary practices.
The Path Forward for IsoPet® Therapy
As Vivos Inc. continues on its trajectory of innovation, the company aims to introduce more clinics to IsoPet therapy, thereby reaching a broader scope of animal patients in need of effective cancer treatments. The emphasis on utilizing already established facilities ensures that the transition towards adopting IsoPet therapy is seamless and beneficial for both pet owners and veterinary practices.
Frequently Asked Questions
What is IsoPet® Precision Radionuclide Therapy™?
IsoPet® is an advanced cancer treatment designed for small animals that utilizes targeted radiation to effectively destroy tumors while minimizing harm to surrounding tissues.
How does the certification process for clinics work?
The certification process involves Vivos Inc. assisting clinics in navigating regulatory requirements, including obtaining or amending radioactive material licenses, alongside providing comprehensive training.
Why is Yttrium-90 important in this therapy?
Yttrium-90 is crucial because it emits localized radiation directly where it is needed, allowing for effective tumor treatment without affecting nearby healthy organs.
What are the main advantages of IsoPet therapy compared to traditional treatments?
IsoPet therapy allows for a higher localized dose of radiation, can be administered in an outpatient setting, and generally results in fewer side effects compared to traditional external beam radiation therapies.
Is IsoPet therapy FDA approved?
Yes, the FDA recognizes IsoPet as a medical device, confirming its safety and intended use in treating specific types of cancers in animals.
